- Allarity Therapeutics, Inc. presented new and updated clinical data from its ongoing Phase 2 clinical trial for **stenoparib/2X-121** in advanced ovarian cancer patients at the AACR 7th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025.  **[1860657_0001213900-25-090872_ea0258492-8k_allarity.htm:0]** **[1860657_0001213900-25-090872_ea025849201ex99-1_allarity.htm:0]** 
- The Kaplan-Meier analysis showed that the median Overall Survival (mOS) for patients receiving stenoparib/2X-121 twice daily has now **exceeded 25 months**.  **[1860657_0001213900-25-090872_ea025849201ex99-1_allarity.htm:0]** **[1860657_0001213900-25-090872_ea025849201ex99-1_allarity.htm:1]** 
- This mOS is approximately **10 months longer** than the mOS reported for the most recent FDA approvals and advances in therapy for platinum-resistant ovarian cancer patients.  **[1860657_0001213900-25-090872_ea025849201ex99-1_allarity.htm:1]** 
- Clinical benefit was evident in patients with **BRCA wild-type as well as BRCA mutated genetics**, with two patients continuing on therapy for over 24 months.  **[1860657_0001213900-25-090872_ea025849201ex99-1_allarity.htm:0]** 
- An amended Phase 2 trial protocol, specifically for platinum-resistant or platinum-ineligible patients, has begun enrolling to accelerate stenoparib's clinical development towards FDA approval.  **[1860657_0001213900-25-090872_ea025849201ex99-1_allarity.htm:2]**

Allarity Therapeutics Reports New Clinical Data for Stenoparib in Advanced Ovarian Cancer

- Allarity Therapeutics, Inc. entered into a Securities Purchase Agreement and a Registration Rights Agreement on **September 22, 2025**.  **[1860657_0001213900-25-090197_ea025831001ex10-2_allarity.htm:0]** **[1860657_0001213900-25-090197_ea025831001ex10-1_allarity.htm:0]** **[1860657_0001213900-25-090197_ea0258310-8k_allarity.htm:1]** **[1860657_0001213900-25-090197_ea0258310-8k_allarity.htm:4]** 
- The company agreed to sell **1,562,500 shares** of common stock and/or pre-funded warrants in a private placement, with shares priced at **$1.60** and pre-funded warrants at **$1.5999**.  **[1860657_0001213900-25-090197_ea0258310-8k_allarity.htm:1]** **[1860657_0001213900-25-090197_ea025831001ex10-1_allarity.htm:4]** 
- The initial closing, scheduled for **September 23, 2025**, is expected to generate approximately **$2.5 million** in gross proceeds for the company.  **[1860657_0001213900-25-090197_ea0258310-8k_allarity.htm:1]** 
- The investor has the right for **90 calendar days** following the initial closing to purchase additional shares and/or pre-funded warrants for aggregate gross proceeds of **$7.5 million**.  **[1860657_0001213900-25-090197_ea0258310-8k_allarity.htm:1]** **[1860657_0001213900-25-090197_ea025831001ex10-1_allarity.htm:4]**

Allarity Therapeutics Enters into Securities Purchase Agreement for Private Placement

- Allarity Therapeutics, Inc. announced on **August 26, 2025**, that the **U.S. Food and Drug Administration (FDA)** granted **Fast Track designation** to **stenoparib**, its investigational treatment for **advanced ovarian cancer**.  **[1860657_0001213900-25-080923_ea025463201ex99-1_allarity.htm:0]** **[1860657_0001213900-25-080923_ea0254632-8k_allarity.htm:1]** 
- This designation is intended to **expedite the development and review** of drugs for serious conditions with unmet medical needs, potentially allowing for accelerated approval and priority review.  **[1860657_0001213900-25-080923_ea025463201ex99-1_allarity.htm:0]** 
- The company recently began patient enrollment for a **new Phase 2 clinical trial** evaluating stenoparib in advanced ovarian cancer, with the **first patient enrolled in early June 2025**.  **[1860657_0001213900-25-080923_ea025463201ex99-1_allarity.htm:0]** 
- The trial is designed to accelerate the clinical development of stenoparib and its **DRP® companion diagnostic**.  **[1860657_0001213900-25-080923_ea025463201ex99-1_allarity.htm:0]**

Allarity Therapeutics (ALLR)